Form 4: Apogee Therapeutics CEO Michael Henderson Sells 15,000 Shares
SEC Form 4 Filing
Apogee Therapeutics CEO Michael Henderson sold 15,000 shares of common stock on July 5, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Michael Henderson, CEO of Apogee Therapeutics, sold 15,000 shares of common stock on July 5, 2024.
- The sale was executed under a Rule 10b5-1 trading plan adopted on September 25, 2023.
- The shares were sold at a weighted average price of $37.26, with individual prices ranging from $36.78 to $37.60.
- Following the transaction, Henderson beneficially owns 1,474,487 shares of Apogee Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating a routine stock sale by the CEO. The sale was conducted under a pre-arranged trading plan, suggesting it's not necessarily indicative of a negative outlook. Therefore, the sentiment is neutral.
Industry Context
Sales by company executives are a normal part of corporate governance. It is important to note that the sale was executed under a pre-arranged 10b5-1 trading plan, which is a common practice to avoid accusations of insider trading.
Stakeholder Impact
- The stock sale could have a minor impact on shareholder sentiment, but the pre-arranged nature of the sale mitigates potential concerns.
Key Dates
| Date | Description |
|---|---|
| 2023-09-25 | Date of adoption of Rule 10b5-1 trading plan |
| 2024-07-05 | Date of transaction (stock sale) |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.